EGFR and non-small cell lung carcinoma: The most widely used targeted agents, epidermal growth factor receptor–tyrosine kinase inhibitors (EGFR–TKIs), have been determined to significantly prolong survival in EGFR‐mutant patients with NSCLC.3, 4